COPD
Chronic obstructive pulmonary disease — treatable, and treated as if it weren't
What it is
COPD is a progressive lung disease causing persistent airflow limitation that does not fully reverse — encompassing emphysema (destruction of the air sacs) and chronic bronchitis (inflamed, mucus-producing airways). It is diagnosed by spirometry, it is massively underdiagnosed, and it is one of the leading causes of death worldwide.
Why it matters
COPD carries two beliefs that are both wrong and both harmful. The first is that it is untreatable — a diagnosis to be endured rather than managed. It is not: treatment reduces symptoms, exacerbations and hospital admissions, triple inhaler therapy has shown a mortality signal in selected patients, and pulmonary rehabilitation is one of the most effective interventions in all of medicine while being one of the most under-referred. The second belief is that it is self-inflicted, and therefore somehow less deserving of care. Smoking is by far the dominant cause, and that fact is a reason to help people stop — not a reason to treat them with less seriousness. Stigma in COPD is not merely unkind; it delays diagnosis and worsens outcomes.
What BioSignal knows about treating this
What works for COPD
BioSignal’s clinical summary, most important first.
- SMOKING CESSATION — the only intervention proven to slow the decline in lung function. Nothing else comes close
- Pulmonary rehabilitation — highly effective for symptoms, quality of life and admissions, and drastically under-referred
- Long-acting bronchodilators (LAMA/LABA) — first-line inhaled therapy
- Inhaled corticosteroids — for exacerbators, guided by blood eosinophils. Not for everyone; they raise pneumonia risk
- Triple therapy in selected patients — reduces exacerbations, with a mortality signal
- Vaccination (influenza, pneumococcal, COVID-19, RSV)
- Long-term oxygen therapy where chronic hypoxaemia is present — improves survival
Signal Records relevant to this condition
Interventions and contributing factors — some of these records describe a cause rather than a cure. The rating shown is BioSignal’s confidence in that Signal Record, not a claim about how well it treats this condition. Open any of them for the full evidence.
- Inhaled CorticosteroidsHigh confidence
The cornerstone of asthma treatment: fewer attacks, fewer admissions, fewer deaths. Reliever-only treatment is no longer recommended at any severity. Not the steroids used in sport. In COPD the indication is narrow — exacerbators with higher eosinophils — and pneumonia risk rises.
- N-Acetylcysteine (NAC)Moderate confidence
A life-saving antidote that has been repackaged as a wellness supplement. The overdose evidence does not transfer to a healthy person taking a capsule.
- Vitamin DHigh confidence
Effective for deficiency and for bone health in at-risk groups. For broad disease prevention in adults who are already replete, the largest trials are null — and confidence in that null is high. Routine testing of healthy adults is not supported.
- Vitamin CHigh confidence
Does not prevent colds — one of the best-tested negatives in nutrition. Shortens them slightly, but only if you were already taking it. Megadoses are mostly excreted: absorption saturates around 200 mg/day. Genuinely useful for iron absorption, and genuinely essential — scurvy is still real.
- AlcoholHigh confidence
A Group 1 carcinogen with dose-dependent harms. The heart-protection belief does not survive the methods designed to test it. Cutting back helps, even without quitting.
New to this? Read these first
How this usually unfolds
- Recognize risk factors
- Get diagnosed
- Track key biomarkers
- Lifestyle first
- Evidence-based treatment
- Long-term monitoring
Who is at risk
- Smoking — by far the dominant cause
- Second-hand smoke
- Biomass fuel exposure (a major global cause, often in people who never smoked)
- Occupational dust, fumes and chemical exposure
- Alpha-1 antitrypsin deficiency — genetic, underdiagnosed, and worth testing for at least once
- Poor lung development in childhood, including from severe childhood respiratory infection
- Age
How it's diagnosed
COPD requires SPIROMETRY. It cannot be diagnosed on symptoms alone, and it is very commonly missed — people attribute years of breathlessness and 'smoker's cough' to age or to being unfit, and present only when substantial lung function has already been lost. Anyone over 40 with persistent breathlessness, chronic cough or sputum and a history of exposure should have spirometry. Alpha-1 antitrypsin deficiency should be tested for at least once, particularly in younger patients or those with limited smoking history.
Key biomarkers
Lifestyle
Explore this condition across BioSignal
Related Foundations
Related Signal Records
Related body systems
Frequently asked questions
What is COPD?
A progressive lung disease in which the airways are inflamed and narrowed and the air sacs are damaged, so airflow is persistently limited and does not fully reverse. It shows up as breathlessness, chronic cough and sputum, and periods of sudden worsening called exacerbations. It is diagnosed with a breathing test called spirometry, and it is very commonly missed for years because people put the symptoms down to age, to smoking, or to being out of shape.
Is COPD treatable?
Yes — and the widespread belief that it is not is doing real harm, because people who think nothing can be done do not seek the things that can. The lung damage already present cannot be reversed. But treatment reduces symptoms, reduces exacerbations, reduces hospital admissions, and in selected patients triple inhaler therapy has shown a signal of reduced mortality. Pulmonary rehabilitation — a structured exercise and education programme — is one of the most effective interventions in the whole of medicine for this disease, and it is badly under-referred. If you have COPD and have never been offered it, ask.
Is it too late to stop smoking?
No. This is the most important question on the page and the answer is not a platitude. Smoking cessation is the ONLY intervention proven to slow the decline in lung function in COPD — no drug does this — and it works at any age and at any stage of the disease. It will not restore what has been lost, and it changes the slope of everything that comes next. If you take one thing from this page: it is not too late, and it is the single highest-impact thing available to you.
What's the difference between asthma and COPD?
Both obstruct airflow, and they are genuinely different diseases. Asthma is variable and largely REVERSIBLE — it comes and goes, and the airways open up with a bronchodilator. COPD is persistent and does not fully reverse. Asthma usually begins in childhood and is often allergic; COPD usually appears after 40 and is usually driven by smoking or other inhaled exposure. The treatment logic differs too: in asthma an inhaled steroid is the cornerstone for everyone, while in COPD it is reserved for people who keep exacerbating, guided by their blood eosinophil count, because it raises pneumonia risk. Some people have features of both, which is a real clinical picture and not a fudge.
Should I be on a steroid inhaler for my COPD?
It depends, genuinely — and unlike in asthma, 'everyone should' is the wrong answer. Inhaled steroids in COPD help people who keep having exacerbations despite bronchodilators, and they help most when the blood eosinophil count is higher. If your eosinophils are low and you are not exacerbating, the benefit is small and the increased risk of pneumonia is real. Your eosinophil count is probably already sitting in a blood test you have had. It is one of the few numbers in medicine that genuinely changes what you should be prescribed.
Evidence summary
COPD is characterised by persistent, incompletely reversible airflow limitation confirmed by spirometry, and is substantially underdiagnosed. Smoking cessation is the only intervention demonstrated to slow the rate of decline in lung function, and it is effective at any age and stage. Pulmonary rehabilitation has strong randomised evidence for improving exercise capacity, quality of life and reducing hospital admissions after exacerbations, and is widely under-referred. Long-acting bronchodilators are first-line inhaled therapy. Inhaled corticosteroids reduce exacerbations in patients with an exacerbation history, with benefit concentrated in those with higher blood eosinophil counts, and increase the risk of pneumonia; eosinophil-guided use is recommended. Large trials of triple therapy have shown reduced exacerbations with a mortality signal in selected patients. Long-term oxygen therapy improves survival in chronic hypoxaemia. Alpha-1 antitrypsin deficiency is an underdiagnosed genetic cause and testing is recommended at least once. High-dose N-acetylcysteine has been studied as a mucolytic with modest and contested effects on exacerbations.
References & sources
- GOLD Global Strategy for the Diagnosis, Management and Prevention of COPD
- IMPACT and ETHOS trials of triple inhaler therapy
- Cochrane reviews of pulmonary rehabilitation in COPD
Educational information — not medical advice
Is this condition page clear, accurate, and useful? Your feedback shapes what we review next.
Give feedback